公开(公告)号：US10774036B2

公开(公告)日：2020-09-15

申请号：US16472386

申请日：2017-12-20

Applicant: Novartis AG

Inventor： Florian Karl Kleinbeck-Riniker ,  Tobias Kapferer ,  Hongyong Kim ,  Jie Ku ,  Kurt Laumen ,  Yunzhong Li ,  Wei Peng ,  Thomas Ruch ,  Thierry Schlama ,  Yao Yang

IPC: C07C227/06 ,  C07C229/36 ,  C12P41/00

Abstract: The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone.

公开(公告)号：US11891401B2

公开(公告)日：2024-02-06

申请号：US17281528

申请日：2019-10-08

Applicant: NOVARTIS AG

Inventor： Yudong Cao ,  Siyi Jiang ,  Hongyong Kim ,  Andreas Kordikowski ,  Irene Xia ,  Bo Yu ,  Jing Zhang ,  Yi Zhao

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  C07C57/15 ,  A61P33/02

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P33/02 ,  C07C57/15 ,  C07B2200/13

Abstract: The application relates to N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide (Compound I) fumaric acid co-crystals and X-ray amorphous complexes of Compound (I) and fumaric acid. The application also provides methods of making the same; pharmaceutical compositions comprising them; and their use in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a kinetoplastid parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.